Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES TAKEDA<br />
Product Class Date Terms of Agreement<br />
LU AA21004 & LU<br />
AA24530<br />
N 2007 Co-development & co-commercialization with Lundbeck<br />
in the USA & Japan of several Lundbeck pipeline<br />
compounds for mood & anxiety disorders. Initial focus will<br />
be on LU AA21004 & LU AA24530, with option under<br />
certain conditions to include 2 other compounds of the<br />
same class in earlier development. If approved, both will<br />
co-promote in the USA & Japan. Lundbeck will receive<br />
initial $40m up to $345m in milestones. They will jointly<br />
complete development, with Takeda booking total sales &<br />
funding most of development. Lundbeck will receive a<br />
share of the revenue generated in the USA & Japan as<br />
well as royalty payments on Takeda’s share of revenues.<br />
CBP 501 L 2007 Agreement with CanBas granting Takeda exclusive rights<br />
to develop, manufacture and market this and backup<br />
cancer compounds worldwide, except in the US where<br />
activity will be jointly conducted. CanBas, a G2<br />
checkpoint abrogater (injection) is currently in a phase I<br />
trial in the US for malignant mesotherioma, lung cancer.<br />
XEN 401 M 2006 Xenon entered into an exclusive licensing agreement with<br />
Takeda for the development and commercialization of<br />
oral formulations of XEN 401 in Japan and certain other<br />
Asian countries. Xenon will receive a $75 million upfront<br />
fee, and will be eligible to development, regulatory and<br />
sales-based milestone payments. Takeda will also buy $5<br />
million in Xenon stock. Takeda confirmed preparation for<br />
clinical studies, ongoing in 2008.<br />
HuL 2G7 L 2006 Galaxy granted Takeda exclusive, worldwide rights to<br />
develop, manufacture and market HuL 2G7. Galaxy will<br />
receive an upfront $2 million licensing fee from Takeda,<br />
as well as milestone payments dependent on the<br />
achievement of certain development and regulatory<br />
milestones. Galaxy will also be entitled to royalties on<br />
product sales.<br />
Hematide (pegylated<br />
erythropoietin receptor<br />
agonist, Affymax)<br />
B 2006 Affymax initially granted Takeda rights to develop and<br />
commercialize Hematide in Japan. Subsequently they<br />
signed an agreement to collaborate on the development<br />
and co-commercialization of Hematide in the USA, and<br />
Takeda will hold an exclusive development and<br />
commercialization license outside the USA. Affymax is to<br />
receive an upfront cash payment of $105 million, as well<br />
as being eligible to receive development and regulatory<br />
milestone payments of up to $280 million, and<br />
commercialization milestone payments of $430 million.<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 96
Change language